Resource library: Reagent resource for studying SARS-CoV-2 variants
Posted: 23 February 2021 | Sino Biological Inc. | No comments yet
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK’s B.1.1.7, Brazil’s P.1.
Sino Biological has developed 80+ recombinant RBD/Spike and Nucleocapsid protein mutants carrying the mutations of high interest, such as N501Y and E484K identified in three new fast-spreading SARS-CoV-2 variants, UK’s B.1.1.7, Brazil’s P.1, and South Africa’s B.1.351, emerging in recent months, to support evaluating the efficacy of the antibodies and vaccination.
Related content from this organisation
- Sino Biological announces construction of its new US-Based centre for bioprocessing
- Application note: Afucosylated mAb expression & antibody efficacy
- Whitepaper: Recombinant protein expression using a BEVS
- Sino Biological and Ainnocence partner to offer next-generation antibody development CRO services
- Sino Biological invests over 200M RMB to establish new subsidiaries in Taizhou and Suzhou, China
Related topics
Antibodies, Biomarkers, Biopharmaceuticals, Disease Research, Immunology
Related organisations
Sino Biological Inc.
